|
Name |
Pentacosane
|
Molecular Formula | C25H52 | |
IUPAC Name* |
pentacosane
|
|
SMILES |
CCCCCCCCCCCCCCCCCCCCCCCCC
|
|
InChI |
InChI=1S/C25H52/c1-3-5-7-9-11-13-15-17-19-21-23-25-24-22-20-18-16-14-12-10-8-6-4-2/h3-25H2,1-2H3
|
|
InChIKey |
YKNWIILGEFFOPE-UHFFFAOYSA-N
|
|
Synonyms |
PENTACOSANE; n-Pentacosane; 629-99-2; BON9H94Y8V; NSC-158663; Pentacosane, analytical standard; UNII-BON9H94Y8V; EINECS 211-123-6; MFCD00009353; Pentacosane, 99%; NSC 158663; AI3-36478; DTXSID2060882; CHEBI:32938; HSDB 8355; CH3-[CH2]23-CH3; HY-N7494; ZINC6920418; LMFA11000582; NSC158663; AKOS015843190; LS-15134; DB-054365; CS-0130240; FT-0632671; P0139; D91907; Q151007; 2A4605C9-A088-458C-AD58-AA987FF6C408
|
|
CAS | 629-99-2 | |
PubChem CID | 12406 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 352.7 | ALogp: | 13.1 |
HBD: | 0 | HBA: | 0 |
Rotatable Bonds: | 22 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 0.0 | Aromatic Rings: | 0 |
Heavy Atoms: | 25 | QED Weighted: | 0.142 |
Caco-2 Permeability: | -5.205 | MDCK Permeability: | 0.00000424 |
Pgp-inhibitor: | 0 | Pgp-substrate: | 0 |
Human Intestinal Absorption (HIA): | 0.003 | 20% Bioavailability (F20%): | 0.106 |
30% Bioavailability (F30%): | 1 |
Blood-Brain-Barrier Penetration (BBB): | 0.008 | Plasma Protein Binding (PPB): | 99.54% |
Volume Distribution (VD): | 4.893 | Fu: | 0.96% |
CYP1A2-inhibitor: | 0.052 | CYP1A2-substrate: | 0.141 |
CYP2C19-inhibitor: | 0.134 | CYP2C19-substrate: | 0.056 |
CYP2C9-inhibitor: | 0.027 | CYP2C9-substrate: | 0.97 |
CYP2D6-inhibitor: | 0.091 | CYP2D6-substrate: | 0.022 |
CYP3A4-inhibitor: | 0.15 | CYP3A4-substrate: | 0.017 |
Clearance (CL): | 4.377 | Half-life (T1/2): | 0.013 |
hERG Blockers: | 0.436 | Human Hepatotoxicity (H-HT): | 0.004 |
Drug-inuced Liver Injury (DILI): | 0.423 | AMES Toxicity: | 0.008 |
Rat Oral Acute Toxicity: | 0.017 | Maximum Recommended Daily Dose: | 0.041 |
Skin Sensitization: | 0.974 | Carcinogencity: | 0.019 |
Eye Corrosion: | 0.996 | Eye Irritation: | 0.927 |
Respiratory Toxicity: | 0.266 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC000434 | 0.961 | D00AOJ | 0.795 | ||||
ENC000446 | 0.959 | D07ILQ | 0.478 | ||||
ENC000401 | 0.924 | D00STJ | 0.472 | ||||
ENC000442 | 0.918 | D00FGR | 0.465 | ||||
ENC000435 | 0.890 | D0Z5SM | 0.427 | ||||
ENC000432 | 0.877 | D05ATI | 0.364 | ||||
ENC000359 | 0.872 | D0O1PH | 0.363 | ||||
ENC000436 | 0.859 | D0T9TJ | 0.357 | ||||
ENC000915 | 0.841 | D0Z1QC | 0.335 | ||||
ENC000591 | 0.840 | D00MLW | 0.331 |